WPG Advisers
PVLA icon

WPG Advisers’s Palvella Therapeutics PVLA Stock Holding History

WPG Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.1K Hold
8
– – ﹤0.01% 1319
2026
Q2 		$1.22K Hold
8
– – ﹤0.01% 1299
2026
Q1 		$997 Buy
8
+1
+14% +$104 ﹤0.01% 1257
2025
Q4 		$733 Buy
+7
New +$597 ﹤0.01% 1338

Other funds holding PVLA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

WPG Advisers's PVLA Position: Q3 2026 in Review

WPG Advisers held its Palvella Therapeutics (PVLA) position steady in Q3 2026 at 8 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1319.

WPG Advisers first reported a position in PVLA in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.22K in Q2 2026. 141 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • WPG Advisers held 8 shares of Palvella Therapeutics worth $1.1K as of Q3 2026.
  • WPG Advisers left its Palvella Therapeutics share count unchanged in Q3 2026.
  • Palvella Therapeutics made up ﹤0.01% of WPG Advisers's portfolio in Q3 2026, its #1319 holding.
  • WPG Advisers first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • WPG Advisers's Palvella Therapeutics position peaked at $1.22K in Q2 2026.
  • 141 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on WPG Advisers's 13F filing for Q3 2026, filed 27 Oct 2026.